-
2 months ago | 
cancernetwork.com | Rohit Gosain |Rahul Gosain |Sarah L. Sammons
2 Commerce Drive Cranbury, NJ 08512
-
2 months ago | 
cancernetwork.com | Rohit Gosain |Rahul Gosain |Sarah L. Sammons
February 17, 2025By Panelists discuss how; the treatment of HER2-positive metastatic breast cancer typically involves HER2-targeted therapies combined with chemotherapy. First-line treatment usually consists of trastuzumab plus pertuzumab with a taxane. Subsequent lines may include T-DM1, tucatinib-based combinations, or other HER2-directed therapies, with treatment selection guided by disease characteristics and prior therapy response. Related Content Related Content
-
2 months ago | 
cancernetwork.com | Rohit Gosain |Rahul Gosain |Sarah L. Sammons
February 17, 2025By Panelists discuss how, locally advanced HER2-positive breast cancer is characterized by overexpression of HER2 proteins with regional spread beyond the primary tumor, involving either extensive lymph node involvement, chest wall, or skin, but without distant metastases. Treatment typically combines targeted HER2 therapy, chemotherapy, and local interventions. Related Content Related Content
-
Jan 17, 2025 | 
oncologynewscentral.com | Arya Roy |Sarah L. Sammons
At the Oncology Brothers live event, Advancements in Oncology, coinciding with SABCS in San Antonio, Dr. Arya Mariam Roy (The Ohio State University Comprehensive Cancer Center) interviewed Dr. Sarah Sammons (Dana-Farber Cancer Institute, Harvard Medical School), who served on the Triple-Negative Breast Cancer panel.
-
Nov 29, 2024 | 
targetedonc.com | Sarah L. Sammons
Sarah Sammons, MD, medical oncologist, clinical investigator in the Breast Oncology Center, associate director of the Metastatic Breast Cancer Program, Dana-Farber Cancer Institute, discusses some of the challenges seen with different regimens for HER2-positive metastatic breast cancer treatment The treatment landscape for HER2-positive metastatic breast cancer has significantly improved in recent years, with the introduction of 2 highly effective regimens: trastuzumab deruxtecan (Enhertu;...
-
Nov 10, 2024 | 
journals.sagepub.com | Jayant Y. Gadrey |Sarah L. Sammons |Nancy Lin |Stacey Pan
IntroductionIn recent years, there have been significant strides toward developing effective therapeutic options for patients with metastatic breast cancer (MBC).
-
Nov 2, 2024 | 
targetedonc.com | Sarah L. Sammons
Sarah Sammons, MD, medical oncologist, clinical investigator in the Breast Oncology Center, associate director of the Metastatic Breast Cancer Program, Dana-Farber Cancer Institute, discusses findings from an analysis of the DESTINY-Breast03 trial (NCT03529110) regarding trastuzumab deruxtecan (Enhertu; T-DXd) vs trastuzumab emtansine (Kadcyla; T-DM1) in the context of HER2-positive breast cancer with brain metastases.
-
Oct 28, 2024 | 
targetedonc.com | Sarah L. Sammons
Sarah Sammons, MD, medical oncologist, clinical investigator in the Breast Oncology Center, associate director of the Metastatic Breast Cancer Program, Dana-Farber Cancer Institute, highlights the need for further investigation into trastuzumab deruxtecan (Enhertu; T-DXd) in breast cancer treatment. In this interview, she explains some areas for future research of T-DXd based on findings from an analysis of the DESTINY-Breast03 trial (NCT03529110).
-
Oct 21, 2024 | 
targetedonc.com | Sarah L. Sammons
Sarah Sammons, MD, medical oncologist, clinical investigator in the Breast Oncology Center, associate director of the Metastatic Breast Cancer Program, Dana-Farber Cancer Institute, discusses some of the problems seen with brain metastasis in HER2-positive metastatic breast cancer. In HER2-positive metastatic breast cancer, brain metastasis is a significant challenge that requires careful attention.
-
Sep 16, 2024 | 
targetedonc.com | Sarah L. Sammons
Sarah Sammons, MD, medical oncologist, clinical investigator in the Breast Oncology Center, associate director of the Metastatic Breast Cancer Program, Dana-Farber Cancer Institute, provides an overview of the DESTINY-Breast03 trial (NCT03529110).
